Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus

Alicia Martinez-Lopez a, Mirjana Persaud a, Maritza Puray Chavez b, Hongjie Zhang c, Lijun Rong d, Shufeng Liu e, Tony T. Wang e, Stefan G. Sarafianos b, Felipe Diaz-Griffero a,⁎

a Department of Microbiology and Immunology, Albert Einstein College of Medicine Bronx, NY 10461, USA
b Laboratory of Biochemical Pharmacology Emory University, Emory University, Atlanta, GA 30322, USA
c School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Hong Kong SAR, People’s Republic of China
d Microbiology and Immunology College of Medicine, University of Illinois at Chicago, IL 60612, USA
e Laboratory of Vector-borne Viral Diseases, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20903, USA

ARTICLE INFO

Article history:
Received 29 May 2019
Received in revised form 24 August 2019
Accepted 24 August 2019
Available online 6 September 2019

Keywords:
Zika
Glycosylated diphyllin
Fusion
Endosomal
pH
Ifnar1−/−

ABSTRACT

Background: Flaviviruses such as Zika cause sporadic pandemic outbreaks worldwide. There is an urgent need for anti-Zika virus (ZIKV) drugs to prevent mother-to-child transmission of ZIKV, new infections in high-risk populations, and the infection of medical personnel in ZIKV-affected areas.

Methods: Here, we showed that the small molecule 6-deoxyglucose-diphyllin (DGP) exhibited anti-ZIKV activity both in vitro and in vivo. DGP potently blocked ZIKV infection across all human and monkey cell lines tested. DGP also displayed broad-spectrum antiviral activity against other flaviviruses. Remarkably, DGP prevented ZIKV-induced mortality in mice lacking the type I interferon receptor (Ifnar1−/−). Cellular and virological experiments showed that DGP blocked ZIKV at a pre-fusion step or during fusion, which prevented the delivery of viral contents into the cytosol of the target cell. Mechanistic studies revealed that DGP prevented the acidification of endosomal/lysosomal compartments in target cells, thus inhibiting ZIKV fusion with cellular membranes and infection.

Findings: These investigations revealed that DGP inhibits ZIKV infection in vitro and in vivo.

Interpretation: The small molecule DGP has great potential for preclinical studies and the ability to inhibit ZIKV infection in humans.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Zika virus (ZIKV) is a mosquito-borne flavivirus that recently caused an outbreak in humans, which resulted in fetal abnormalities such as microcephaly and neurological diseases in adults including Guillain-Barré syndrome [1–3]. ZIKV, which belongs to the Flaviviridae family along with several other important vector-borne human pathogens such as the West Nile virus (WNV), dengue virus 1 (DENV1), tick-borne encephalitis virus (TBEV), and Japanese encephalitis virus (JEV). Some of these viruses are widespread in the equatorial region, where the mosquito vectors are most prevalent [4–6]. Although ZIKV is known to be primarily transmitted through mosquito bites, some studies have shown that it can also be sexually transmitted [7–9]. For these reasons, ZIKV was recognized in 2016 as a Public Health Emergency of International Concern by the World Health Organization (WHO).

ZIKV is an enveloped virus with a 10.7-kb positive-sense, single-stranded RNA genome that encodes a polyprotein, which is post-translationally processed into three structural proteins (Capsid/C; premembrane/prM; and Envelope/E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [10–15]. The structural proteins protect the genome and help in virus entry into and exit from the cell, and also serve as targets for the host antibody-mediated immune response. On the other hand, the non-structural proteins are required for replication of the viral genome, processing of polyproteins, and restriction of the host innate immune response [4–6].

The study of ZIKV infection in animal models has been possible due to the availability of mice strains that are susceptible to infection. A commonly used strain is the C57BL/6 mouse that contains a knockout of the type I interferon (IFN) receptor (Ifnar1−/−) [16–20]. Upon ZIKV challenge, these mice display viral infection in the central nervous system (CNS), gonads, serum, and other vital organs, which eventually leads to mortality. Other ZIKV infection models include the Irf3−/−/−...
Implications of all the available evidence

The small molecule DGP potently inhibits Zika virus infection at very low concentrations (nM range) while its toxicity is undetectable. Furthermore, this compound effectively prevents Zika virus-induced death in mice. Altogether this evidence shows the great potential of DGP for preclinical studies.

Research in context

Evidence before this study

Zika virus is a mosquito-borne flavivirus that caused the 2016 outbreak in Brazil. Because Zika virus infection has been associated with neurological disorders such as Guillain-Barre syndrome and microcephaly in newborns, the recent Zika outbreak has been declared a public health emergency concern by the World Health Organization. There is an urgent need for novel antivirals with the potential to be used in the clinic. These novel antivirals are indispensable to prevent new Zika virus infections in high-risk populations, infection of medical personnel in Zika virus affected areas, and mother-to-child transmission of Zika virus.

Added value of this study

Here we discovered a new small molecule with the ability to block Zika virus infection in human cells (in vitro) and in mice (in vivo). 6-deoxyglucose-diphyllin (DGP) is a broad-spectrum antiviral that potently block infection by Zika, Dengue, Yellow fever, tick-borne encephalitis, Japanese encephalitis, West Nile and Ebola viruses. DGP targets the cellular endosomal acidification, preventing the entry of the virus into the cell consequentially inhibiting infection. Because of its effectiveness against Zika virus infection in mice, this new inhibitor shows great potential for its use in the clinics.

2. Methods

2.1. Contact for reagent and resource sharing

Further information and requests for resources should be directed to and will be fulfilled by Dr. Felipe Diaz-Griffero (felipe.diaz-griffero@einstein.yu.edu).

2.1. Contact for reagent and resource sharing

In vitro and in vivo infections were performed in a biosafety level 2 (BSL-2) room. Mice experiments were approved by the Albert Einstein College of Medicine Institutional Animal Care and Use Committee (IACUC) and performed according to the guidelines of the approved animal protocol (#20170210). Certified personnel carried out all procedures. Humane endpoint criteria in compliance with IACUC-approved scoring parameters were used to determine when the animals should be humanely euthanized.

2.2.2. Mouse studies

Mice were purchased from Jackson Laboratories and bred in a specific-pathogen-free facility at Albert Einstein College of Medicine. C57BL/6 mice that are knockout for the type I IFN receptor alpha and beta [Stock No. 32045-JAX IFN-αR (−/−)−/−, Jackson Laboratories] were used for ZIKV challenges. Groups with 6 mice each (3–4 week-old, females and males) were subcutaneously injected (footpad) using 30 μL of PBS containing the indicated amount of DGP, with or without 5 PFUs of ZIKV. Mortality, symptoms, and body weight of each mouse were monitored for 15 post-challenge days.

2.2.2. Mouse studies

In vitro and in vivo infections were performed in a biosafety level 2 (BSL-2) room. Mice experiments were approved by the Albert Einstein College of Medicine Institutional Animal Care and Use Committee (IACUC) and performed according to the guidelines of the approved animal protocol (#20170210). Certified personnel carried out all procedures. Humane endpoint criteria in compliance with IACUC-approved scoring parameters were used to determine when the animals should be humanely euthanized.

2.2.2. Mouse studies

Mice were purchased from Jackson Laboratories and bred in a specific-pathogen-free facility at Albert Einstein College of Medicine. C57BL/6 mice that are knockout for the type I IFN receptor alpha and beta [Stock No. 32045-JAX IFN-αR (−/−)−/−, Jackson Laboratories] were used for ZIKV challenges. Groups with 6 mice each (3–4 week-old, females and males) were subcutaneously injected (footpad) using 30 μL of PBS containing the indicated amount of DGP, with or without 5 PFUs of ZIKV. Mortality, symptoms, and body weight of each mouse were monitored for 15 post-challenge days.

2.2.2. Mouse studies

Mice were purchased from Jackson Laboratories and bred in a specific-pathogen-free facility at Albert Einstein College of Medicine. C57BL/6 mice that are knockout for the type I IFN receptor alpha and beta [Stock No. 32045-JAX IFN-αR (−/−)−/−, Jackson Laboratories] were used for ZIKV challenges. Groups with 6 mice each (3–4 week-old, females and males) were subcutaneously injected (footpad) using 30 μL of PBS containing the indicated amount of DGP, with or without 5 PFUs of ZIKV. Mortality, symptoms, and body weight of each mouse were monitored for 15 post-challenge days.

2.2.2. Mouse studies

Mice were purchased from Jackson Laboratories and bred in a specific-pathogen-free facility at Albert Einstein College of Medicine. C57BL/6 mice that are knockout for the type I IFN receptor alpha and beta [Stock No. 32045-JAX IFN-αR (−/−)−/−, Jackson Laboratories] were used for ZIKV challenges. Groups with 6 mice each (3–4 week-old, females and males) were subcutaneously injected (footpad) using 30 μL of PBS containing the indicated amount of DGP, with or without 5 PFUs of ZIKV. Mortality, symptoms, and body weight of each mouse were monitored for 15 post-challenge days.

2.2.2. Mouse studies

Mice were purchased from Jackson Laboratories and bred in a specific-pathogen-free facility at Albert Einstein College of Medicine. C57BL/6 mice that are knockout for the type I IFN receptor alpha and beta [Stock No. 32045-JAX IFN-αR (−/−)−/−, Jackson Laboratories] were used for ZIKV challenges. Groups with 6 mice each (3–4 week-old, females and males) were subcutaneously injected (footpad) using 30 μL of PBS containing the indicated amount of DGP, with or without 5 PFUs of ZIKV. Mortality, symptoms, and body weight of each mouse were monitored for 15 post-challenge days.

2.2.2. Mouse studies

Mice were purchased from Jackson Laboratories and bred in a specific-pathogen-free facility at Albert Einstein College of Medicine. C57BL/6 mice that are knockout for the type I IFN receptor alpha and beta [Stock No. 32045-JAX IFN-αR (−/−)−/−, Jackson Laboratories] were used for ZIKV challenges. Groups with 6 mice each (3–4 week-old, females and males) were subcutaneously injected (footpad) using 30 μL of PBS containing the indicated amount of DGP, with or without 5 PFUs of ZIKV. Mortality, symptoms, and body weight of each mouse were monitored for 15 post-challenge days.
2.3. Detection of infection by ZIKV strain MR766

The methodology used to detect ZIKV strain MR766 was previously described in [35]. In detail, cells were seeded in 24-well plates and infected with ZIKV strain MR766 at the indicated MOI for 48 h. Subsequently, cells were detached using 5 mM ethylenediaminetetraacetic acid (EDTA) in PBS, collected by centrifugation, and fixed with 1.5% paraformaldehyde in PBS for 15 min. The cells were then resuspended in a humidified 5% CO2 incubator for 1 h at 4 °C followed by 20 min at 65 °C to inactivate the enzyme. For actin detection, Oligo-dT was used to reverse transcribe total RNA. qRT-PCR was carried out using SYBR green in a 20-μL final volume reaction using a Mastercycler proS machine. The primers used to detect ZIKV were: 5′-TTGGTCATGATACTGCTGATTGC-3′ (forward) and 3′-Reverse (Genome position 332–697) (NM_002176.2) and for actin detection: 5′-CATGGAGGAGCTCTCTGATGTGCTG-3′-Reverse (Genome position 1123–1103) (AY632532.2). For the detection of SeV, we followed the same procedure:

- 5′-CCAGGAGGACAGATCTTCCATGTGTT-3′-Reverse (Genome position 332–307) (M30202.1).

For the detection of IFN-β, we followed the procedure:

- 5′-ACCTCGAAATCAGATCTCTACAACTTCTCA-3′ (Genome position 644–668) and Reverse 5′-TCTGATGACTTCTCTGAGTGGTCGGTTCCATCTGCTATCGTGT-3′-Reverse (Genome position 718–697) (NM_002176.2) and for actin detection: 5′-AACCCACCCCGATCATGAGCTG-3′-Forward and 5′-CCGGAGATTCTTCCAGAGTACCATG-3′-Reverse. In the graphs, the data is presented as folds of induction normalized to actin.

2.5. In situ (+)-ZIKV RNA hybridization

ZIKV RNA in cultured adherent cells was probed using RNAscope reagents and protocol (Advanced Cell Diagnostics) [40], with some modifications as previously described [41]. Fixed cells on coverslips were washed twice with PBS, then incubated with 0.1% Tween-20 in PBS (PBS-T) for 10 min at room temperature (RT) and washed in PBS for 1 min. Coverslips were immobilized on glass slides, followed by protease treatment (Pretreat 3) that was diluted 1:2 in PBS and incubated on the sample in a humidified HybEZ oven at 40 °C for 15 min. The slides were washed twice with PBS for 1 min. ZIKV-specific target probe, V-ZIKA-pp-O2, for the (+) RNA (Catalog number, 464531; Advanced Cell Diagnostics) was added to the coverslip and incubated in a humidified HybEZ oven at 40 °C for 2 h. Two consecutive wash steps in 1× wash buffer (Catalog number, 310091; Advanced Cell Diagnostics) were performed on a rocking platform at RT for 2 min in every wash step after this point, and all incubations were performed in a humidified HybEZ oven at 40 °C. cDNA amplification was performed using a series of amplifiers (RNAscope; Advanced Cell Diagnostics). Amplifier hybridization 1-Fluorescent (Amp 1-FL) was added to the coverslip for 30 min, followed by Amp 2-FL hybridization for 15 min. Amp 3-FL hybridization was then added for 30 min, followed by Amp 4-FL hybridization for 15 min. Nuclei were stained with DAPI (Advanced Cell Diagnostics).
for 1 min at RT. Coverslips were washed 2 times in PBS, detached, and mounted on slides using ProLong Gold Antifade reagent (Thermo Fisher Scientific). Images were obtained using the Leica TCP SP8 inverted confocal fluorescence microscope using a 63×1.4 oil-immersion objective. The excitation/emission bandpass wavelengths used to detect DAPI and Alexa-fluor 488 were set to 405/420–480 and 488/505–550, respectively. In order to quantify the differential drug effects on (+) ZIKV RNA, we manually acquired 25 images of each biological replicate drug treatment experiment and performed cellular analysis.

2.6. Determination of Acidine Orange fluorescence

Acridine Orange (Invitrogen) staining was performed as described previously [42,43]. Cells were stained with 1 μg/mL AO in 10% FBS DMEM for 30 min at 37 °C and then collected by trypsinization. Changes in fluorescence were measured using a Celesta flow cytometer in the PerCP-Cy5–5-A channel.

2.7. Cell viability assay

Cell viability was determined by measuring the reduction of the tetrazolium dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] to its insoluble form formazan [44,45], to show that the ZIKV inhibition effect at any of the tested concentrations.

2.8. Quantification and statistical analysis

To compare the effects of each treatment in relation to its control, all data was analyzed using the two-tailed Student’s t-test. Differences were considered statistically significant at P < .05 (*), P < .01 (**), P < .001 (***) or non-significant (ns).

3. Results

3.1. The small molecule DGP blocks ZIKV infection in human and primate cell lines

We discovered the ability of DGP to inhibit ZIKV infection in human cells by serendipity. We tested the ability of DGP to block ZIKV infection in three different cell lines: African green monkey kidney epithelial cells (VERO), human fibroblast cells (HT1080), and human microglial cells (CHME3). Cells were challenged with the ZIKV strain MR766 at a multiplicity of infection (MOI) of ~0.5 for 48 h in the presence of DGP at the indicated concentrations (Fig. 2B). ZIKV-RVP infection was measured by detecting GFP expression using flow cytometry, as previously described [35]. ZIKV infection was almost completely blocked at concentrations of ~0.25–0.50 μM of DGP (Fig. 2B). The inhibitory concentration 50 (IC50) ranged between 0.042 and 0.070 μM (Fig. 2A). This pattern was observed in all three cell types, regardless of the species. As a control, we used the 3-[(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which measures conversion of MTT to its insoluble form formazan [44,45], to show that the ZIKV inhibitory concentrations of DGP were not toxic to cells (Fig. S2). Overall, these results demonstrated that DGP is a potent inhibitor of ZIKV infection in human and primate cell lines.

In addition to the MR766 strain of ZIKV, we tested the ability of DGP to block infection of four different ZIKV strains: PRVABC59 (Puerto Rico), DAK ArDr-51,254 (Senegal), bGH10656 (Nigeria), and the strain recently implicated in the 2016 outbreak, iBeH819015 (Brazilian). CHME3 cells were challenged with the different strains at the indicated concentrations of DGP, and infection was determined 48 h post-infection by measuring the percentage of infected cells by flow cytometry using 4G2 antibodies. As shown in Fig. 2C, the same inhibition pattern is observed for all of them, following a dose dependent manner, being the infection almost undetectable at 1 μM. The IC50 values ranged from 0.022 to 0.052 μM (Fig. 2C). These experiments showed that DGP inhibits all tested ZIKV strains.

To understand whether DGP has virucidal activity, we incubated 107 PFUs of ZIKV MR766 with 10, 100 or 500 μM of DGP for 1 h at 37 °C. Subsequently, the viral titer for each mixture was determined in human CHME3 cells (Fig. S3). As shown in Fig. S3, DGP did not show virucidal effect at any of the tested concentrations.

3.2. DGP blocks ZIKV infection prior to or during viral fusion

To determine the ZIKV life cycle stage at which DGP acts, we first used two approaches to measure the production of viral RNA: 1) In situ hybridization to image viral RNA by using fluorescent probes, and 2) qRT-PCR to quantify viral RNA. To image viral RNA, VERO cells were challenged with the ZIKV strain MR766 at an MOI of ~0.5 in the presence of 1 μM DGP, which potently blocks infection. At 48 h post-infection, cells were fixed/permeabilized and ZIKV positive-strand RNA was detected by in situ hybridization using a specific fluorescently labeled negative-strand probe (green). Cell nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI; blue). Twenty-five random images were captured for each treatment (Mock, ZIKV MR766, and ZIKV MR766 + DGP 1 μM) and a representative image is shown in Fig. 3A. Inhibition of viral RNA production correlated with the inhibition of viral infection (Fig. 3C, lower panels). Altogether, these results suggested that DGP blocks ZIKV infection before or during viral RNA synthesis.

To corroborate these findings, we used qRT-PCR to quantify viral RNA using specific primers for the ZIKV genome (Fig. 3C). VERO and HT1080 cells were challenged with ZIKV at an MOI of 1 in the presence of DGP at the indicated concentrations (Fig. 3C). At 48 h post-infection, ZIKV RNA was quantified by qRT-PCR, and normalized to Actin. The synthesis of viral RNA was completely inhibited in the presence of increasing concentrations of DGP in both cell lines (Fig. 3C, upper panels). Inhibition of viral RNA production correlated with the inhibition of viral infection (Fig. 3C, lower panels). Altogether, these results suggested that DGP blocks ZIKV infection before or during viral RNA synthesis. However, the question of whether DGP imposes a pre- or post-fusion block to ZIKV infection remains unanswered.

To investigate whether DGP imposes a pre- or post-fusion block to ZIKV infection, we performed a time-of-drug addition experiment for DGP and compared the pattern of inhibition to that of known pre-fusion inhibitors of ZIKV infection, such as Nanchangmycin and ammonium chloride (NH4Cl). We challenged HT1080 cells with ZIKV-RVP at
an MOI of ~0.5, and added 1 μM of DGP, 1 μM of Nanchangmycin, or 20 mM of NH4Cl at the indicated time points. Infection was measured at 48 h post-infection by calculating the percentage of GFP-positive cells (Fig. 3D). We found that the inhibition of infection was stronger when the drug was added at earlier time points. Interestingly, DGP followed the same pattern of inhibition when compared with Nanchangmycin and NH4Cl, suggesting that DGP imposes a pre-fusion block to ZIKV infection.

ZIKV infection activates the type I IFN response [46–48] via IFN-stimulated genes that are activated by the host after recognition of viral components [48]. If ZIKV is inhibited at a pre-fusion step, viral nucleic acids and proteins will not be exposed to the host cytosol; thus the type I IFN response will not be activated. To test whether DGP treatment prevents activation of the type I IFN response, we challenged CHME3 cells using ZIKV MR766 at an MOI of 1 in the presence of different DGP concentrations. At 48 h post-challenge, we assessed the type I IFN response by using qRT-PCR to measure IFN-β induction (Fig. 3E, upper panel), as previously described [49]. Consistent with the notion that DGP imposes a pre-fusion block to ZIKV infection, we found that treatment with DGP prevented the activation of the type I IFN response (Fig. 3E, upper panel). Treatment with NH4Cl, which prevents viral fusion [35,50–57], also inhibited IFN-β induction. In both DGP and NH4Cl treatments, viral infection was inhibited, as demonstrated by using the 4G2 antibody (Fig. 3E, lower panel), as previously described [35]. These results suggested that DGP inhibits ZIKV infection prior to or during the fusion step.

The Flaviviridae family of viruses encode a glycoprotein that is necessary to achieve fusion at the endosomal/lysosomal membranes, the step that releases viral components into the cytoplasm [55,58]. To further understand the mechanism of DGP action, we investigated the effects of DGP on viruses that do not require the fusion step at the endosomal membrane to complete their replication cycle, such as the Sendai Virus (SeV), which fuses at the plasma membrane [59–61]. To this end, we infected CHME3 cells with SeV at MOI of ~2.5, ~5 or ~10 in the presence of DGP (1 μM) or NH4Cl and measured IFN-β production and viral infection. We found that DGP did not inhibit IFN-β production in SeV-infected cells (Fig. 3F, upper panel). Consistently, DGP treatment did not inhibit SeV infection (Fig. 3F, lower panel). Interestingly, SeV showed increased infection after DGP or NH4Cl treatment (Fig. 3F, lower panel), which resulted in higher induction of IFN-β compared with the control cells (Fig. 3F, upper panel). Our results showed that DGP does not inhibit SeV infection or the resultant induction of the type I IFN response. A possible explanation for this phenomenon is that a fraction of SeV in any given infection is endocytosed and degraded by the cell; however, when lysosomotropic agents (compounds that prevent the acidification of endosomes such as DGP or NH4Cl) are used, the degradation of SeV decreases and there is more intact virus, which results in an increased infection.

Overall, these results are in agreement with the notion that DGP blocks ZIKV infection at a pre-fusion step or during fusion at the endosomal membrane.

3.3. DGP inhibits the infectivity of other flaviviruses

Our findings have demonstrated that DGP is a potent inhibitor of ZIKV infection. Next, we tested whether DGP inhibits other Flaviviridae viruses. For this purpose, we used reporter viral particles (RVPs) expressing GFP as a reporter of infection, and containing the envelope of: DENV1, TBEV, WNV, or JEV. We also included RVPs of the Ebola virus (EBV), which belongs to the Filoviridae family, in our analysis. VERO cells were challenged with the indicated RVPs in the presence of increasing concentrations of DGP (Fig. 4). At 48 h post-challenge, infection was determined by using flow cytometry to measure the percentage of GFP-positive cells. We found that DGP showed dose-dependent inhibitory activity against all the RVPs tested. As control, cells were infected with the RVPs in the presence of 20 mM of NH4Cl, which inhibited infection of all the tested RVPs (Fig. 4). DGP-mediated inhibition of RVP-infection was comparable to that mediated by NH4Cl. These results showed that DGP exerts antiviral activity against different flaviviruses, demonstrating its potential use as a broad-spectrum antiviral agent.

3.4. DGP prevents ZIKV-induced mortality in type I interferon receptor knockout mice (Ifnar1−/−)

Next, we tested the antiviral activity of DGP in vivo by using the mouse model C57BL/6 Ifnar1−/− [16–19], which is a knockout mouse for the type I IFN receptor α and β. To this end, we inoculated the footpad of Ifnar1−/− mice using 5 plaque forming units (PFUs) of the ZIKV strain MR766, which provides a lethal amount of virus, in conjunction with DGP. Mice that were 3–4 week-old were divided in groups (6 mice/group) and injected with the following mixtures: phosphate-buffered saline (PBS; Mock-injected), ZIKV, ZIKV +0.1 mg/kg of DGP, or ZIKV +0.2 mg/kg of DGP (Fig. 5A). Body weight and virus-induced symptoms were monitored daily in the mice for 15 days post-challenge (Fig. 5B). The group inoculated with ZIKV showed a rapid decrease in body weight, and succumbed to viral infection at day 8 post-challenge, as shown by the Kaplan-Meier plot (Fig. 5A and B); this group displayed the following phenotypes: limb paralysis, lethargic behavior, tremors, and weight loss. The group that was challenged with ZIKV +0.1 mg/kg of DGP showed similar symptoms and succumbed to viral infection at day 10 post-challenge. However, the group injected with ZIKV +0.2 mg/kg of DGP showed a delay in the appearance of symptoms when compared with the ZIKV group, and some mice survived until day 14 (Fig. 5A and B). These results indicated that DGP delayed the appearance of symptoms and delayed ZIKV-induced mortality by a few days compared with control mice.

To test whether increasing DGP concentrations increased survival in ZIKV-injected mice, three groups (6 mice/group) were injected with the following mixtures: PBS + 1 mg/kg of DGP, ZIKV, or ZIKV +1 mg/kg of DGP (Fig. 5C and D). The weight and virus-induced symptoms were monitored daily in the mice for 15 post-challenge days. As previously observed, the group inoculated with ZIKV showed a rapid decrease in body weight, and succumbed to viral infection 7–9 days post-challenge, as shown by the Kaplan-Meier plot (Fig. 5C). In contrast, all six mice in the group challenged with ZIKV +1 mg/kg of DGP survived for the length of the experiment (Fig. 5C). Two independent experiments are shown (Experiment #1 and #2). Although in experiment #1 the group injected with ZIKV +1 mg/kg of DGP showed lower body weight when compared to the group that was injected PBS + 1 mg/kg of DGP (Fig. 5D), the group injected with ZIKV +1 mg/kg of DGP did not show any obvious disease symptoms during the course of both experiments. These results demonstrated that DGP effectively inhibits ZIKV infection in vivo when co-injected with the virus suggesting that DGP could potentially be used to prevent or treat ZIKV infection in vivo.

Next we investigated whether DGP affects viral replication in the brain and spleen in mice that was challenged with ZIKV in conjunction with DGP. To this end, we determined viral loads by qRT-PCR using

---

Fig. 2. DGP inhibits ZIKV infection of HT1080, VERO, and CHME3 cells. HT1080, VERO, and CHME3 cells were challenged with ZIKV-MR766 (A) or ZIKV-RVPs (B) at an MOI of ~1 in conjunction with increasing concentrations of DGP. At 48 h post-challenge, infection was determined by measuring the percentage of 4G2-positive and GFP-positive cells for ZIKV-MR766 and ZIKV-RVP infections, respectively. (C) CHME3 cells were challenged with ZIKV PRVABC59, ZIKV IbeH19015, ZIKV IbeH1605, and ZIKV DAK ArD-51254 at an MOI of 1, 0.2, 0.2 and 0.5, respectively. 48 h post-challenge, infection was determined by measuring the percentage of 4G2-positive cells. The IC50 and selectivity index (SI) values are shown for each of the dose-dependent curve. The SI was calculated by the ratio of C50 to C90. Experiments were repeated at least three times and results of a representative experiment are shown. Bars represent the Mean ± SD. P < .05 (*), P < .01 (**), P < .001 (***), or not significant (ns), using two-tailed Student’s t-test are shown.
specific primers against the ZIKV genome six days post-challenge. As shown in Fig. 5E, the use of 1 mg/kg of DGP completely inhibits the occurrence of viral replication in the brain that correlates with protection against ZIKV-induced death; however, a small amount of viral replication can be detected in the spleen, which may not be sufficient to cause death. These experiments suggested that DGP is preventing the virus to reach the brain, hence conferring a higher rate of survival.

3.5. The active principle of DGP is diphyllin

DGP is a diphyllin derivative in which the hydroxyl group is substituted with 6-deoxy-D-glucose (6DG) (Figs. 1 and 6A). To understand the active component of DGP that contributes to its antiviral activity, we tested the individual abilities of diphyllin and 6DG to inhibit ZIKV infection (Fig. 6B and C). To this end, we challenged human HT1080 and CHME3 cells with ZIKV (MOI of 1) in the presence of increasing concentrations of the indicated drug (Fig. 6B and C), and monitored infection for 48 h post-challenge by measuring the percentage of 4G2-positive cells. We found that diphyllin blocked ZIKV infection in HT1080 cells with an IC_{50} of ~0.06 μM, whereas the IC_{50} of DGP was ~0.02 μM (Fig. 6B). Similarly, for CHME3 cells (Fig. 6C), the IC_{50} for Diphyllin was ~0.21 μM, whereas the IC_{50} of DGP was ~0.04 μM. These results indicated that diphyllin is the active component of DGP that contributes to its antiviral activity. By contrast, 6DG did not show antiviral activity against ZIKV infection (Fig. 6B and C). Interestingly, DGP was ~2–4-fold more potent than diphyllin, which suggested that the addition of 6DG to diphyllin contributes to increased antiviral activity. As control, we used the MTT assay test to ensure that the concentrations of diphyllin and DGP required to inhibit ZIKV infection were not toxic to human or monkey cells (Fig. S2). Our results suggested that the active component of DGP is diphyllin, and that 6DG contributes to the potency of DGP.
3.6. DGP inhibits ZIKV fusion by preventing acidification of endosomes

Previous studies have shown that diphyllin affects the expression of vacuolar-ATPase, resulting in changes to the pH gradients in cells [62,63]. Vacuolar-ATPases are cellular proton pumps that are crucial for processes that maintain pH gradients in the cell, such as the acidification of endosomes [64]. Because DGP blocks ZIKV infection at a pre-fusion step, we decided to test whether DGP inhibited ZIKV infection by preventing the acidification of endosomes and lysosomes. For this purpose, we used Acridine Orange (AO), a cell-permeable fluorescent dye marker that accumulates in low pH compartments such as endosomes and lysosomes [42]. Within these acidic cellular compartments, AO displays orange fluorescence [42,65]; however, this orange fluorescence dramatically decreases in the presence of compounds that prevent acidification of endosomes, such as the vacuolar ATPase inhibitor Bafilomycin A1 [42,65].

To test whether DGP prevents endosomal/lysosomal acidification, we pre-incubated HT1080 cells with 2 μM, 1 μM, or 0.1 μM of DGP for 4 h and then stained cells using 1 μg/mL of AO (Fig. 7). Changes in fluorescence were measured using a Celesta flow cytometer in the PerCP-Cy5-5-A channel. As shown in Fig. 7, increasing DGP concentrations resulted in decreased AO fluorescence in HT1080 cells, suggesting that DGP prevents the acidification of endosomal and lysosomal compartments. As positive controls, we used Bafilomycin A1 and NH₄Cl, both of which prevent endosomal and lysosomal acidification [65]. Consistent with our hypothesis, DGP and Bafilomycin A1 treatments showed similar decreases in AO fluorescence (Fig. 7A and B). Diphyllyn also prevented the acidification of endosomes and lysosomes albeit to a lower extent when compared with DGP (Fig. 7). Consistent with our previous results (Fig. 6), 6DG did not prevent the acidification of endosomes and lysosomes (Fig. 7). The loss of red fluorescence intensity compared with stained non-treated control cells is shown as mean...

Fig. 4. DGP blocks infectivity of other Flaviviruses. DENV1, JEV, TBEV, WNV, and EBV reporter viral particles expressing GFP were used to challenge VERO cells in the presence of increasing concentrations of DGP. At 48 h post-challenge, infection was determined by measuring the percentage of GFP-positive cells using a flow cytometer. Infection values were normalized to the values of infection without DGP. Experiments were repeated at least three times and results of a representative experiment are shown. Bars represent the Mean ± SD. P < .05 (*), P < .01 (**), P < .001 (***) or not significant (ns), using two-tailed Student’s t-test are shown.
fluorescence intensity (MFI) in Fig. 7B. These results suggested that DGP prevents the acidification of endosomes/lysosomes, which is required for the fusion of ZIKV [35,50–52], thus resulting in the inhibition of ZIKV infection.

4. Discussion

Our study has discovered that the natural compound DGP has the ability to potently inhibit ZIKV infection in human cell lines (in vitro) and in mice (in vivo). In addition, DGP shows broad-spectrum antiviral activity by blocking other flaviviruses such as DENV1, TBEV, WNV, and JEV. We also found that the active component of DGP is the diphillin molecule, which, by itself, is less potent against ZIKV compared with DGP. Mechanistic studies revealed that DGP inhibits ZIKV infection at a pre-fusion step or during fusion of the virus. Our study also shows that DGP prevents the acidification of endosomes and therefore, inhibits the fusion of the viral membrane with the cellular membrane.

DGP inhibits ZIKV infection in vitro in different monkey and human cell lines without triggering cellular toxicity. Our results demonstrated that DGP concentrations in the nanomolar range (IC50 = 10–70 nM (0.01–0.07 μM)) inhibit ZIKV infection. In contrast, inhibition of ZIKV infection by chloroquine, a drug that also inhibits ZIKV fusion by preventing acidification of endosomes, requires concentrations in the micromolar range [35,50,66,67]. Based on our data, DGP is a better inhibitor when compared to Nanchangmycin, which inhibits ZIKV infection at an IC50 = -100 – 400 nM [52]. Interestingly, Nanchangmycin, like DGP, also blocks viral entry, but not by preventing acidification of endosomes (data not shown). Recent observations have suggested that Nanchangmycin blocks viral internalization/endoctyosis [68].

A combination of experiments allowed us to conclude that DGP inhibits ZIKV infection at a pre-fusion step or during fusion. In situ hybridization studies showed that DGP prevents the replication of viral RNA. The use of qRT-PCR to detect ZIKV RNA in cells treated with DGP confirmed the lack of viral RNA replication in these cells. Consistent with these results, we showed that DGP prevents the activation of the type I IFN response by ZIKV infection. Altogether, our results indicated that DGP prevents the entry of ZIKV contents into the host cytosol, suggesting that the DGP-induced block is at a pre-fusion step or during viral fusion.

DGP is a broad-spectrum antiviral that not only potently blocks ZIKV infection, but also inhibits infection by other flaviviruses. This makes DGP an ideal candidate for the clinical treatment of flaviviruses. However, despite blocking infection of every flavivirus tested in this work, DGP failed to block SeV infection, suggesting that the drug has a certain degree of specificity towards flaviviruses. In spite of its broad antiviral activity, DGP may still prove to be an effective anti-ZIKV drug, and may address the urgent need to combat new ZIKV infections in high-risk populations, infection of medical personnel in ZIKV affected areas, and prevent mother-to-child transmission of ZIKV.

Our results showed that DGP prevents ZIKV-induced mortality in the type I Interferon receptor knockout mice (Ifnar1−/−). C57BL/6 Ifnar1−/− mice were subcutaneously challenged (footpad) with 5 PFUs of the ZIKV strain MR766 in conjunction with the indicated amounts of DGP solubilized in PBS. Mortality (A,C) and body weight (B,D) were monitored daily for 15 days post-challenge. Mock challenges were performed using PBS alone. Each challenged group contained 6 mice, which were 3–4 week-old. Mice were weighed daily, excluding the day that they were found dead or sacrificed. Weights are expressed as percentage of body weight prior to infection, and standard deviations are shown. (E) Three independent groups of mice were challenged by injecting ZIKV (5 PFU) in conjunction with 0.2 mg/kg, or 1 mg/kg of DGP. As a control, mice were only injected with ZIKV (5 PFU). Mice were sacrificed 6 days post-infection and used to determine viral loads in brain (upper panel) and spleen (lower panel). Organs were lysed, and total RNA was extracted using TRIzol as described in Methods. Total RNA was used to determine the levels of ZIKV RNA by qRT-PCR using specific primers against ZIKV. Viral RNA levels were normalized to actin. Log-Rank (Mantel-Cox) test is shown.

This work utilizes as an animal model of ZIKV infection, the type I interferon knockout mouse. All our infections were performed in 3–4 week-old mice (Ifnar1−/−). C57BL/6 Ifnar1−/− mice were subcutaneously challenged (footpad) with 5 PFUs of the ZIKV strain MR766 in conjunction with the indicated amounts of DGP solubilized in PBS. Mortality (A,C) and body weight (B,D) were monitored daily for 15 days post-challenge. Mock challenges were performed using PBS alone. Each challenged group contained 6 mice, which were 3–4 week-old. Mice were weighed daily, excluding the day that they were found dead or sacrificed. Weights are expressed as percentage of body weight prior to infection, and standard deviations are shown. (E) Three independent groups of mice were challenged by injecting ZIKV (5 PFU) in conjunction with 0.2 mg/kg, or 1 mg/kg of DGP. As a control, mice were only injected with ZIKV (5 PFU). Mice were sacrificed 6 days post-infection and used to determine viral loads in brain (upper panel) and spleen (lower panel). Organs were lysed, and total RNA was extracted using TRIzol as described in Methods. Total RNA was used to determine the levels of ZIKV RNA by qRT-PCR using specific primers against ZIKV. Viral RNA levels were normalized to actin. Log-Rank (Mantel-Cox) test is shown.
weeks-old mice with ZIKV MR766, as shown in [18,21]. However, it has been reported that infection of 7–10 weeks-old mice by ZIKV MR766 does not lead to death [74]. Overall these different results showed the limitations of our mouse model, and suggested that ZIKV-induced death depends on many factors such as mouse age, viral dose, and route of inoculation, as previously discussed [75]. Although the type I
A

Bafilomycin A (100 nM)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

NH\textsubscript{4}Cl (25 mM)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

DGP (2 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

DGP (1 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

DGP (0.1 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

Diphyllyn (2 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

Diphyllyn (1 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

Diphyllyn (0.1 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

6DG (2 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

6DG (1 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

6DG (0.1 \textmu M)

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]

\[ \text{Counts} \]
interferon knockout mice has the limitation that is defective in innate antiviral responses [20], this mouse model is transnationally and clinically relevant due to the following features: 1) ZIKV infection of this mouse occurs in similar organs causing similar diseases when compared to humans (brain, testis, spleen, and the eye) [75], 2) ZIKV infection of this mouse reproduces the neurological symptoms observed in humans such as tremors, ataxia and paralysis [75], and 3) ZIKV infection of this mouse is reverted by the use of small molecules or antibodies against the virus supporting its relevance on evaluating vaccines and therapeutics [75]. Overall the type I interferon knockout mouse is a robust model to perform preclinical studies in the search of new therapies for ZIKV infection.

To investigate the part of the molecular structure of DGP responsible for the inhibition of ZIKV infection, we separately analyzed the two components of DGP, 6DG and Diphyllin. Our results showed that diphyllin is the active component of DGP, causing ZIKV inhibition. Interestingly, diphyllin was less potent than DGP, indicating that 6DG showed a small but measurable contribution towards DGP’s ability to inhibit ZIKV infection. Studies have suggested that diphyllin has several cellular functions, as follows: 1) it inhibits vacuolar-ATPase activity [62,76]; 2) it inhibits endosomal acidification [63]; and 3) it inhibits topoisomerase IIa [31,32]. We and others have previously suggested that ZIKV infection is affected by inhibiting endosomal acidification [35,53–57]. In agreement with the literature, we showed that both diphyllin and DGP prevent endosome acidification to inhibit ZIKV infection. However, DGP is more potent in preventing endosomal acidification when compared with diphyllin, thus suggesting the additive effect of 6DG in DGP-induced ZIKV inhibition. Overall, we have identified the inhibition mechanism of a novel compound DGP that blocks ZIKV infection both in vitro and in vivo.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.08.060.
[21] Tripathi S, Balasubramaniam VR, Brown JA, Menia L, Grant A, Bardina SV, et al. A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory responses. PLoS Pathog 2017;13(2):e1006258.

[22] Rossi SI, Tesh RB, Azar SR, Munuza AE, Hanley KA, Auguste AJ, et al. Characterization of a novel murine model to study Zika virus. Am J Trop Med Hyg 2016;94(6):1362-5.

[23] Dinh KD, Graham VA, Rayner E, Atkinson B, Hall G, Watson RJ, et al. A susceptible mouse model for Zika virus infection. PLoS Negl Trop Dis 2016;10(5):e0004658.

[24] Zmukro J, Marques RE, Schols D, Verbeken E, Kapitein SJ, Neyts J. The viral polymerase inhibitor 7-Deaza-2′,3′-dideoxyadenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust in vivo mouse model. PLoS Negl Trop Dis 2016;10(5):e0004695.

[25] Smith DR, Holliday B, Daye S, Zeng X, Blanchett C, Kuzki P, et al. Natural respiratory tropism of Zika virus in a highly susceptible immunocompetent mouse model after antibody blockade of type I interferon. PLoS Negl Trop Dis 2017;11(1):e0005296.

[26] Elong Ngono A, Viszczara EA, Tang WW, Sheets N, Joo Y, Kim K, et al. Mapping and role of the CD8+ T cell response during primary Zika virus infection in mice. Cell Host Microbe 2017;21(1):35-46.

[27] Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016;79(3):629-61.

[28] Zhang JH, Rumschlag-Booms E, Yang DY, Liu KL, Li WF, et al. Potent inhibition of drug-resistant HIV-1 strains identified from the medicinal plant Justicia gendarussa. J Nat Prod 2015;78(6):1789-97.

[29] Susplugas S, Hung NV, Bignon J, Thoison O, Cruycyński A, Sevenet T, et al. Cytotoxic responses of human monocytes autonomously trigger type I interferon. Mol Immunol 2018;101:157-66 Pt 1.

[30] Randolph VB, Stollar V. Low pH-mediated induction of cell death in flavivirus-infected Aedes albopictus cell cultures. J Gen Virol 1990;71:1845-50 Pt 8.

[31] Smit JM, Moesker B, Rodenhuis-Zybert I, Wilichutz J. Flavivirus cell entry and membrane fusion. Viruses 2011;3(2):60-71.

[32] Vorovitch MF, Timineev AV, Anadazé SN, Tzougov SM, Kutchach AL, Elbert LB. pH-dependent fusion of tick-borne encephalitis virus with artificial membranes. Arch Virol 1991;118(1):133-8.

[33] Pierson TC, Kielan M. Flaviviruses: braking the entering. Curr Opin Virol 2013;3(1):2-12.

[34] Shu JG, NL. Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol 2004;78(19):10543-55.

[35] Bousse T, Takimoto T, Gorman WL, Takahashi T, Partner A. Regions on the ncmgulin-neuraminidase proteins of human parainfluenza virus type 1 and Sendai virus important for membrane fusion. Virology 1994;204(2):506-14.

[36] Scheid A, Choppin PW. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of protolytic cleavage of an inactive precursor protein of Sendai virus. Virology 1974;57(2):475-90.

[37] Faisca P, Desmeyt D. Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date. Rev Sci Technol 2007;26(1):115-25.

[38] Sheng W, Zou X, Chen M, Liu P, Shen Y, Huang S, et al. Effects of diphyllyn as a novel V-ATPase inhibitor on gastric adenocarcinoma. Eur J Pharmacol 2011;667(1-2):98-108.

[39] Soerenсен MG, Henriksen K, Neustadt-Wiuff AV, Dziegel MH, Mardal D. Diphyllyn, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacuna and bone resorption. J Bone Miner Res 2007;22(10):1640-9.

[40] Forgac M. Vacular ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 2007;8(11):917-29.

[41] Yoshimori T, Yamamoto A, Maruyama Y, Futa M, Tashiro Y, Balfourm AJ, et al. Identification of a novel inhibitor of vacuolar-type H+ -ATPase activity of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep 2017;7:15771.

[42] Cao B, Parnell LA, Diamond MS, Myrowek IL. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med 2017;214(8):2303-13.

[43] Hackett BA, Cherry S. Flavivirus internalization is regulated by a size-dependent pH-dependent endocytic pathway. J Virol 2017;91(24):12462-7.

[44] Saiz JC, Martin-Acebes MA. The race to Zika. Nat Rev Microbiol 2017;15(11):673-81.

[45] Ishii SA, Mespi C, Pinto A, Fernandes I, Sheets N, Sresta S, et al. Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep 2017;7:15771.

[46] Cao B, Parnell LA, Diamond MS, Myrowek IL. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med 2017;214(8):2303-13.

[47] Saiz JC, Martin-Acebes MA. The race to Zika. Nat Rev Microbiol 2017;15(11):673-81.

[48] Deng YQ, Wang S, Ma F, Aliyari R, Huang HY, et al. 25-hydroxycholesterol provides differential protection from Zika virus infection and its associated congenital microcephaly in mice. J Neuroinflammation 2017;14:99.

[49] Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, et al. Adenosine analog NITD008 is a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacuna and bone resorption. J Bone Miner Res 2007;22(10):1640-9.

[50] Li C, Deng YQ, Wang S, Ma F, Aliyari R, Huang HY, et al. 25-hydroxycholesterol provides differential protection from Zika virus infection and its associated congenital microcephaly in mice. J Neuroinflammation 2017;14:99.

[51] Faisca P, Desmeyt D. Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date. Rev Sci Technol 2007;26(1):115-25.

[52] Sheng W, Zou X, Chen M, Liu P, Shen Y, Huang S, et al. Effects of diphyllyn as a novel V-ATPase inhibitor on gastric adenocarcinoma. Eur J Pharmacol 2011;667(1-2):98-108.

[53] Soerenсен MG, Henriksen K, Neustadt-Wiuff AV, Dziegel MH, Mardal D. Diphyllyn, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacuna and bone resorption. J Bone Miner Res 2007;22(10):1640-9.

[54] Forgac M. Vacular ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 2007;8(11):917-29.

[55] Yoshimori T, Yamamoto A, Maruyama Y, Futa M, Tashiro Y, Balfourm AJ, et al. Identification of a novel inhibitor of vacuolar-type H+ -ATPase activity of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep 2017;7:15771.

[56] Cao B, Parnell LA, Diamond MS, Myrowek IL. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med 2017;214(8):2303-13.

[57] Hackett BA, Cherry S. Flavivirus internalization is regulated by a size-dependent pH-dependent endocytic pathway. J Virol 2017;91(24):12462-7.

[58] Saiz JC, Martin-Acebes MA. The race to Zika. Nat Rev Microbiol 2017;15(11):673-81.

[59] Ishii SA, Mespi C, Pinto A, Fernandes I, Sheets N, Sresta S, et al. Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep 2017;7:15771.

[60] Cao B, Parnell LA, Diamond MS, Myrowek IL. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med 2017;214(8):2303-13.

[61] Saiz JC, Martin-Acebes MA. The race to Zika. Nat Rev Microbiol 2017;15(11):673-81.

[62] Ishii SA, Mespi C, Pinto A, Fernandes I, Sheets N, Sresta S, et al. Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep 2017;7:15771.